Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin

Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.